(Q35929532)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17127704%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

title

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17127704%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

1 reference

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17127704%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Maurizia R Brunetto

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17127704%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

author name string

P Marcellin

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17127704%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

G K K Lau

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17127704%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

S Hadziyannis

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17127704%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

R Jin

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17127704%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

T Piratvisuth

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17127704%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

G Germanidis

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17127704%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

C Yurdaydin

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17127704%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

M Diago

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17127704%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

S Gurel

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17127704%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

M-Y Lai

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17127704%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

P Farci

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17127704%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

M Popescu

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17127704%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

P McCloud

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17127704%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17127704%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

language of work or name

English

0 references

publication date

24 November 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17127704%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17127704%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

volume

56

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17127704%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17127704%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

page(s)

699-705

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17127704%20AND%20SRC:MED&resulttype=core&format=json

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

22 December 2019

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1942152

Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1942152

HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1942152

World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1942152

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1942152

Histological grading and staging of chronic hepatitis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1942152

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1942152

Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1942152

A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1942152

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1942152

Lamivudine vs lamivudine and interferon combination treatment of HBeAg(-) chronic hepatitis B.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1942152

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1942152

Prevalence of HBV precore/core promoter variants in the United States

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1942152

Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1942152

Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1942152

Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1942152

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1942152

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1942152

Hepatitis B genotypes and the response to interferon therapy

24 September 2018

1 reference

12 December 2020

The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B

1 reference

12 December 2020

Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study

1 reference

12 December 2020

Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe

1 reference

12 December 2020

Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen

1 reference

12 December 2020

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

1 reference

12 December 2020

A controlled trial of interferon with or without prednisone priming for chronic hepatitis B

1 reference

12 December 2020

Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon

1 reference

12 December 2020

Identifiers

DOI

10.1136/GUT.2005.089722

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17127704%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17127704%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

PubMed publication ID

17127704

1 reference